Transcode Therapeutics (RNAZ) Treasury Shares (2020 - 2026)

Transcode Therapeutics' (RNAZ) quarterly Treasury Shares came in at $1212.2 in Q1 2026, little changed on a QoQ basis from $1212.2 in Q4 2025.

Transcode Therapeutics (RNAZ) Treasury Shares (2020 - 2026) Analysis & Trends

Transcode Therapeutics (RNAZ) has 4 years of Treasury Shares data on file, last reported at $1212.2 in Q1 2026.

Quarterly Treasury Shares changed N/A year-over-year to $1212.2 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1212.2 (changed N/A YoY) and the FY2025 annual result came in at $1212.2, changed N/A from the prior year.
Treasury Shares was little changed at $1212.2 in Q1 2026, from $1212.2 in the prior quarter.
In the past five years, Treasury Shares ranged from a high of $1212.2 in Q4 2025 to a low of $1212.2 in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Treasury Shares (Qtr)
1	Vertex Pharmaceuticals	139.09 Bn	131.23 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.66 Bn	77.66 Bn	3.93 Bn	36.40 Mn
3	Argenx Se	64.86 Bn	59.67 Bn	1.37 Bn	-
4	Moderna	58.07 Bn	52.93 Bn	52.00 Mn	-
5	BeOne Medicines	41.87 Bn	36.77 Bn	1.53 Bn	-
6	Alnylam Pharmaceuticals	31.45 Bn	28.15 Bn	992.69 Mn	-
7	BioNTech SE	27.90 Bn	9.51 Bn	668.28 Mn	8.96 Mn
8	Insmed	27.40 Bn	26.24 Bn	358.27 Mn	-
9	Royalty Pharma	27.28 Bn	26.45 Bn	-	2.72 Mn
10	Transcode Therapeutics	2.84 Mn	2.84 Mn	-	1,242.07

Download Data